The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
A bis-Benzylidine Piperidone Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 as a Therapy for Cancer
Open accessAbstract
The bis-benzylidine piperidone RA190 covalently binds to cysteine 88 of ubiquitin receptor RPN13 in the 19S regulatory particle and inhibits proteasome function, triggering rapid accumulation of polyubiquitinated proteins. Multiple myeloma (MM) lines, even those resistant to bortezomib, were sensitive to RA190 via endoplasmic reticulum stress-related apoptosis. RA190 stabilized targets of human papillomavirus (HPV) E6 oncoprotein, and preferentially killed HPV-transformed cells. After oral (p.o.) or intraperitoneal (i.p.) dosing of mice, RA190 distributed to plasma and major organs excepting brain, and inhibited proteasome function in skin and muscle. RA190 administration profoundly reduced growth of multiple myeloma and ovarian cancer xenografts, and oral RA190 treatment retarded HPV16+ syngeneic mouse tumor growth, without impacting spontaneous HPV-specific CD8+ T cell responses, suggesting its therapeutic potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A comprehensive two-hybrid analysis to explore the yeast protein interactome
Ito, T., Chiba, T., Ozawa, R., Yoshida, M., Hattori, M., & Sakaki, Y. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061034498 · Cited by 3,566
HADDOCK: A Protein−Protein Docking Approach Based on Biochemical or Biophysical Information
Dominguez, C., Boelens, R., & Bonvin, A. M. J. J. (2003) · Journal of the American Chemical Society · doi:10.1021/ja026939x · Cited by 3,187 · cited 3×
“Ambiguous interaction restraints were imposed to restrict RPN13 Pru active residues to be within 2.0 Å of any RA190 atom (Dominguez et al., 2003).”
BackgroundMethodInfluentialChauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694 · cited 1×
“Additional orally delivered drugs targeting distinct activities of the proteasome are needed to increase dosing flexibility, overcome resistance, and reduce side effects (Chauhan et al., 2005).”
BackgroundUbiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets
Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J., & Brownell, J. E. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3321 · Cited by 563 · cited 2×
“Bortezomib was approved for the treatment of relapsed multiple myeloma (MM) and mantle cell lymphoma (Bedford et al., 2011), and carfilzomib was recently approved for patients with MM progression while on or after treatment with bortezomib and an immunomodulatory agent.”
Background
Cited by
Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy
Deshaies, R. J. (2014) · BMC Biology · doi:10.1186/s12915-014-0094-0 · Cited by 337
Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome
Bridgford, J. L., Xie, S. C., Cobbold, S. A., Pasaje, C. F. A., Herrmann, S., Yang, T., Gillett, D. L., Dick, L. R., Ralph, S. A., Dogovski, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06221-1 · Cited by 297
Targeting Metalloenzymes for Therapeutic Intervention
Chen, A. Y., Adamek, R. N., Dick, B. L., Credille, C. V., Morrison, C. N., & Cohen, S. M. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00201 · Cited by 270
Sha, Z., & Goldberg, A. L. (2014) · Current Biology · doi:10.1016/j.cub.2014.06.004 · Cited by 215
Jung, L. A., Gebhardt, A., Koelmel, W., Ade, C. P., Walz, S., Kuper, J., von Eyss, B., Letschert, S., Redel, C., d'Artista, L., et al. (2017) · Oncogene · doi:10.1038/onc.2016.354 · Cited by 101
Metadata
- Authors
- Anchoori, R. K., Karanam, B., Peng, S., Wang, J. W., Jiang, R., Tanno, T., Orlowski, R. Z., Matsui, W., Zhao, M., Rudek, M. A., Hung, C.-F., Chen, X., Walters, K. J., & Roden, R. B. S.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2013-12
- Volume
- 24
- Issue
- 6
- Pages
- 791-805
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W1997012817
- Cited by
- 162
- References
- 4
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.